p-Hydroxy-cinnamic acid is the isomer of cinnamic acid with anti-mutagenic and anti-tumor activities.

TG4-155 is a brain penetrant prostaglandin EP2 specific antagonist.

Ralinepag, is an orally available agonist of the prostacyclin (IP) receptor.

AM211 is a potent and selective prostaglandin D2 receptor type 2 antagonist with IC50 value of 4.9nM.

AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors.

E7046 is a specific antagonist of the type 4 prostaglandin E2 (PGE2) receptor EP4. It possesses significant antitumor growth activity in multiple preclinical tumor models through modulating myeloid cells, including tumor-associated macrophages and myeloid-derived suppressor cells.

RO1138452 is a selective antagonist of prostacyclin (IP) receptor with pKi of 9.3 ± 0.1 in human platelets.

DG-041 is a potent and selective antagonist of prostanoid EP3 receptor with IC50 of 4.6 nM.

Grapiprant is a selective EP4 receptor antagonist whose physiological ligand is prostaglandin E2 (PGE2).

CJ-42794 is a selective prostaglandin E receptor subtype 4 (EP4) antagonist, inhibits [3H]-PGE2 binding to the human EP4 receptor with a mean pKi of 8.5, a binding affinity that was at least 200-fold selective for the human EP4 receptor than other human EP receptor subtypes (EP1, EP2, and EP3).

Rumodolinl, a analog of prostacyclin, is an agonist of IP receptor that used clinically to treat pulmonary arterial hypertension. It is a vasodilator with antithrombotic and anti-inflammatory properties.

Pizuglanstat is a hematopoietic prostaglandin synthase inhibitor.

Asapiprant is a potent and selective DP1 receptor antagonist with a Ki of 0.44 nM.

Limaprost is a PGE1 analog and potent platelet adhesion inhibitor.

Cloprostenol sodium salt (ICI 80996 sodium salt) is a potent synthetic prostaglandin analogue, acts as a luteolytic agent, and is a PGF2α receptor agonist.

GW627368 is a potent and selective competitive antagonist of prostanoid EP4 receptor (Ki= 100 nM) with additional human TP receptor affinity (Ki= 150 nM).

ONO-AE3-208 is an antagonist of EP4 with Ki of 1.3 nM and exhibits suppression the invasion and metastasis of prostate cancer cells.